A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States

Tufail M Malik[1][*], Kevin M Bakker[1], Rachel J Oidtman[1], Oluwaseun Sharomi[1], Giulio Meleleo[2],

Robert B Nachbar[2], Elamin H Elbasha[1]

[1]Merck & Co., Inc., Rahway, NJ, USA

[2]Wolfram Research, Inc., Champaign, IL, USA

* Corresponding author

E-mail: tufail.malik@merck.com (TM)

Abstract

Streptococcus pneumoniae (SP) is a bacterial pathogen that kills more than 300,000 children

every year across the globe. Multiple vaccines exist that prevent pneumococcal disease, with

each vaccine covering a variable number of the more than 100 known serotypes. Due to the high

effectiveness of these vaccines, each new pneumococcal conjugate vaccine (PCV) introduction

has resulted in a decrease in vaccine-type disease and a shift in the serotype distribution towards

non-vaccine types in a phenomenon called serotype replacement. Here, an age-structured

compartmental model was created that reproduced historical carriage transmission dynamics in

the United States and was used to evaluate the population-level impact of new vaccine

introductions into the pediatric population. The model incorporates co-colonization and serotype

competition, which drives replacement of the vaccine types by the non-vaccine types. The model

was calibrated to historical age- and serotype-specific invasive pneumococcal disease (IPD) data

from the United States. Vaccine-specific coverage and effectiveness were integrated in

accordance with the recommended timelines for each age group. Demographic parameters were

derived from US-population-specific databases, while population mixing patterns were informed

by US-specific published literature on age-group based mixing matrices. The calibrated model

was then used to project the epidemiological impact of PCV15, a 15-valent pneumococcal

vaccine, compared with the status quo vaccination with PCV13 and demonstrated the value of

added serotypes in PCV15. Projections revealed that PCV15 would reduce IPD incidence by

6.04% (range: 6.01% to 6.06%) over 10 years when compared to PCV13.

Introduction

Despite the widespread use of pneumococcal vaccines in the United States (US), *Streptococcus*

pneumoniae (SP) caused nearly 17,400 cases of invasive pneumococcal disease (IPD) in 2021,

and nearly 3,000 associated deaths [1]. Globally the number of deaths in children under 5 is

approximately 300,000 [2].

There are more than 100 SP serotypes (STs) [3] . Only a small fraction of these cause majority of

disease which may vary in frequency and severity by age. Vaccines are only able to target a

portion of pneumococcal STs, and their effectiveness is serotype-specific. Asymptomatic or

symptomatic nasopharyngeal carriage (NPC) of SP in an individual, which is relatively common

in young children [5], may result in SP transmission to other individuals through person-to-

person contact via respiratory droplets. NPC can lead to multiple disease outcomes, including

invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), and

acute otitis media (AOM) [6]. IPD, which includes meningitis and bacteremic pneumonia,

primarily afflicts extremes of ages and those with risk factors [3]. AOM is a condition that

exclusively affects children. Vaccines play a role in preventing NPC, but the necessary immune

response is higher than what is required to prevent disease.

In the US a pediatric vaccination program with a 7-valent pneumococcal conjugate vaccine

(PCV) was introduced in 2000, and building on this composition, a 13-valent PCV was

introduced in 2010, followed by a 15-valent vaccine in 2022, and a 20-valent vaccine in 2023.

Since 1983, a 23-valent pneumococcal polysaccharide vaccine (PPSV23) had been

recommended for all adults 65 years or older. Vaccines targeting additional or different

serotypes, along with those based on other technologies, are currently in development. Since the

introduction of PCVs, the US has seen a dramatic reduction in IPD across all age groups in

vaccine-type (VT) serotypes [3]. There has also been replacement of VTs with non-vaccine types

(NVTs) [7]. Globally, there have been higher levels of replacement than those seen in the US,

sometimes leading to higher overall incidence levels than the pre-vaccine period (for example in

France following PCV13 introduction [8]).

Dynamic transmission models (DTMs) have been used extensively to describe the

epidemiological and biological dynamics of SP transmission in the presence or absence of

vaccination (Table S1 summarizes a review of published models). In this study, a DTM was

developed to quantify the epidemiological impact of ST-specific and age-based vaccination

programs. The model is driven by carriage transmission and assigns each ST into one of the

serotype classes (STCs), which were determined based on their inclusion in different

pneumococcal vaccines. Additionally, the model features indirect effects such as herd immunity

and competition between ST classes, which determines replacement dynamics following vaccine

introduction. The model is flexible, so that it can be used in countries that report disease

incidence with different age-groups, incorporated different vaccines into their vaccine schedules

(e.g., PCV10), want to examine different vaccination policies, or are interested in other

pneumococcal diseases of interest. Here, the model was applied to the US setting by dividing

STs into 11 STCs (outlined in Table 1) and dividing the population into 6 age groups (listed in

Table 2). The model was fitted to historical (2000–2019) US IPD incidence (per 100,000) data,

by incorporating each pneumococcal vaccine in the model according to its time of inclusion in

US immunization programs in respective age groups, and the epidemiological impact of the

continued use of PCV13 versus implementing PCV15 in the pediatric immunization program

was assessed (at the time of this study PCV20 was not yet recommended in peds in the US).

Methods

A deterministic age-structured DTM was developed that described SP carriage transmission

dynamics and disease progression in the presence of age- and serotype-specific pneumococcal

vaccines. In addition to the brief description of the model here, additional details can be found in

the Supplementary Appendix. Real-world data were used to inform parameters for vaccine

effectiveness against disease, coverage rates, duration of protection, and carriage clearance rates.

Published contact matrices [9] were used with suitable adaptation for model age structure to

inform contact matrix within and between age groups. Real-world data are lacking for PCV15

given recent introduction. Population data were used to parameterize the demographic aspects of

the model. The model was calibrated to national-level IPD data in the US to estimate the

probability of SP carriage acquisition per contact, competition between STCs, progression rate

from carriage to disease, and vaccine effectiveness against carriage. Disease incidence data were

stratified by age and grouped into STCs, based on inclusion in various vaccines (Table 1).

Previous studies have employed a similar approach of grouping STs into classes and have

embraced similar assumptions [10, 11, 12, 13] (see Section 3.2.1 of the Supplementary Appendix

for detail). With the calibrated model, epidemiological projections were made under different

pediatric vaccination scenarios keeping a realistic mix of vaccination regimen in the adult

population.

Model overview

The model was based on a system of ordinary differential equations and distinguished

pneumococcal carriage from disease as well as their vaccine protection status, which varied by

age and vaccine type (Fig 1). For example, an unvaccinated person can be either susceptible non-

colonized or colonized with up to three STCs. A fraction of infants is born into the unvaccinated

susceptible non-colonized compartment and remain there until they are vaccinated, become

colonized, or die from causes other than pneumococcal disease. Individuals acquire one or two

STCs simultaneously at an age-specific and time-dependent rate (i.e., per capita force of carriage

acquisition), progressing from non-colonized status to single or double colonization, from single

to double or triple colonization, and from double to triple colonization. The model assumes

simultaneous acquisition of up to two STCs because the acquisition of multiple STCs is

exceedingly unlikely. It was assumed that an individual could be colonized by up to three STCs

concurrently.

Fig 1. Model flowchart. Individuals are born into the non-colonized compartments and can move throughout the system during their lifetime. Upon carriage acquisition, individuals move to the colonized (with a single ST), co-colonized with two STs, or triple-colonized compartments. Colonized individuals can clear carriage of one ST at a time. A proportion of colonized individuals will develop a pneumococcal disease. Vaccination (right arm of flowchart) reduces the chance of carriage acquisition and disease development for vaccine STCs. Vaccine can wane over time, but vaccination history is tracked. Compartments in the left arm of the flowchart are composed of vaccine-naïve and vaccine-waned individuals. Detailed model flowchart is provided in Figure S3-S5.

The rate at which uncolonized persons of a given age group acquire SP and become colonized

depends on the number and type of contacts, the fraction of colonized, co-colonized, and triple-

colonized contacts, and the transmission probability per contact, which varies by age. The

number of contacts are governed by a mixing matrix, where each cell represents the number of

contacts a person of a given age class makes with a person in another age class (Table S4). Upon

recovery, it is assumed that the person does not develop immunity and becomes completely

susceptible again.

Individuals leave the unvaccinated compartments through cohort and continuous vaccination at

given rates and enter the appropriate vaccinated compartment, based on their colonization status.

They remain in a given vaccinated compartment until they die, acquire an additional STC, or

their immunity wanes. Since typical colonization is asymptomatic, individuals can be vaccinated

from any of the four (uncolonized, colonized, double colonized, or triple-colonized)

unvaccinated compartments. Vaccination reduces the risk of carriage acquisition and disease

progression.

In the DTM, the rate of acquisition of a second or third STC is reduced due to competition from

the currently carried STC(s). The competition parameter is determined by the relationship

between the current and the invading STC, and can range from no competition (i.e.,

independence) to complete competition (i.e., exclusion), where the acquisition of the invading

STC is completely blocked by the currently carried STC(s).

Disease occurrence was modeled using a case-carrier ratio that varies by disease manifestation,

age, STC, and vaccine-status. Progression to IPD, AOM, or NBPP was included here, while

other manifestations (such as sinusitis) or further classification (such as bacteremia) could be

included in future analyses.

Model application to the US

135   Individual serotypes were grouped into 11 serotype classes (STCs), based on inclusion in various

136   current, past, and future vaccines, including PCV7, PCV13, PCV15, PCV20, PCV21 (V116),

137   and PPSV23 (Table 1).

138   *Table 1. Model serotype classes (STCs). *: cross protection from 6A antigen.*

STC	STs	PCV7	PCV13	PCV15	PCV20	PPSV23	V116
1	4, 6B, 9V, 14, 18C, 19F, 23F	▓	▓	▓	▓	▓	
2	1, 5		▓	▓	▓	▓	
3	3		▓	▓	▓	▓	▓
4	7F, 19A		▓	▓	▓	▓	▓
5	6A, 6C*		▓	▓	▓		▓
6	22F, 33F			▓	▓	▓	▓
7	9N, 17F, 20					▓	▓
8	8, 10A, 11A, 12F				▓	▓	▓
9	15B				▓	▓	
10	15A, 15C, 16F, 23A, 23B, 24F, 31, 35B						▓
11	NVTs						

The classification is based on whether a ST is targeted by an individual vaccine so that the

assessment of each vaccine can be carried out by grouping some of the classes. For example,

PPSV23 includes STCs 1-4 and STCs 6-9, while V116 includes STCs 3-8 and STC 10.

Corresponding parameters were estimated according to this age and ST grouping.

It is worth noting that the current model offers flexibility in the aggregation of serotypes into

classes. In particular, it includes a broader disaggregation of STs than those present in literature.

Table S1 summarizes the serotype classifications or serogroupings used in published

pneumococcal models.

Each STC was further categorized into 6 age groups described in Table 2.

Table 2. Age groups (AG) used in the model.

AG	Age (years)
Infants	0-1
Toddlers	2-4
Children	5-17
Young Adults	18-49
Adults	50-64
Older Adults	65+

This age grouping is chosen based on the availability of historic IPD incidence data in the US,

which was used as the calibration target. Additionally, these age groups align with vaccination

policy recommendations by the Advisory Committee on Immunization Practices (ACIP) of the

Centers for Disease Control and Prevention (CDC). For instance, pediatric vaccination

historically targets infants, adult vaccination covers older adults, and at-risk groups include

young adults and adults. Future policy considerations related to adult vaccination may involve

expanding age-based vaccination to include adults and older adults.

In addition to the scenarios evaluated here, the model is flexible and can evaluate other vaccine

scenarios, such as reducing the vaccination age from older adults to adults, having sequential

vaccination of different vaccines in an age group, other vaccines, or other potential policy

questions.

Numerical computations, including model calibration and projections, were implemented using

Mathematica® 14.0 (https://reference.wolfram.com/mathematica,

https://reference.wolfram.com/language/ref/NDSolve.html,

https://reference.wolfram.com/language/ref/NIntegrate.html,

https://reference.wolfram.com/language/ref/NMinimize.html).

Model parameters and data sources

168 Baseline values for demographic, epidemiologic, and vaccine inputs of the model were identified

169 through a targeted search of the published literature and public databases.

Demographic parameters

171 A stable equilibrium age distribution (with 2017 as the baseline year) and constant mortality

172 hazards for each age group were assumed, using data from the US Census Bureau website

173 (https://www.census.gov/). Since the implied growth rate was insignificant, constant population

174 was assumed over the analysis time horizon to reduce model complexity.

Contact mixing matrix

Mixing patterns among the population affect the transmission dynamics of an infectious

pathogen. Mixing patterns from Prem *et al*. [9] were adapted to create the 6-age group contact

matrix (see Section 3.1.3 of the Supplementary Appendix). Although transmission among adult

age groups was allowed, it was assumed that there was no transmission of SP from adults to the

pediatric population due to limited evidence of adult-to-child transmission and vast evidence that

child-to-child transmission drives SP dynamics [14, 15, 16].

Vaccine parameters

The model assumed full vaccine compliance (i.e., 3+1 doses in pediatric population) and used the respective age-specific observed vaccine coverage rates (VCRs) over the historical period and anticipated VCRs for projections. VCR in each vaccine-target age group is discussed in Supplementary Appendix. In the model, a distinction between two types of vaccine effectiveness (VE) was made: VEc against carriage acquisition and VEd against pneumococcal disease (VEd was unique for each disease outcome of IPD, AOM, and NBPP). VEs vary by vaccine (PCV13, PCV15, PCV20, and PPSV23), STC, and age group. VEds against NBPP and AOM can be seen in Supplementary Table S10 and S11. VEcs were calibrated in the model.

STC- and age-specific VEds against IPD of all vaccines included in the model were based on clinical trials and real-world-evidence studies (Table 3). VEd of PCV13 against STC1-type (i.e., PCV7 STs) IPD in children was assumed to be identical to published PCV7 VEd [17]. ST-specific VEds for the additional PCV13 serotypes were taken from Moore *et al*. [18]. Since VEds within an STC may vary, VEds for each STC in children were estimated as the incidence-weighted average of individual VEds. There is no consensus regarding the VEd of PCV13 on ST3 [19] (which constitutes STC3). Despite high pediatric coverage levels, real world evidence reveals that the long-term impact of PCV13 has had little to no effect on population-level ST3 incidence. Therefore, VEd against STC3 in the base case was assumed to be equal to the left end point of the 95% confidence interval from Moore *et al*. [18].

Table 3. Vaccine effectiveness against IPD by age and serotype class. (PCV20 was only considered for adult vaccination).

	STC	Pediatric age groups	Young adults	Adults	Older adults
PCV13	**1**	0.96	0.739	0.713	0.677
	2	0.87	0.739	0.713	0.677
	3	0.303[*]	0.256	0.247	0.235
	4	0.883	0.739	0.713	0.677
	5	0.86	0.739	0.713	0.677
	6-11	0			
PCV15	**1-5**	Identical to PCV13 VE			
	6	0.86	0.739	0.713	0.677
	7-11	0			
PCV20	**1-6**	Identical to PCV15 VE			
	7	0			
	8, 9	NA	0.739	0.713	0.677
	10, 11	0			
PPSV23	**1-4, 6-9**	NA	0.585	0.559	0.521
	5,10,11	NA	0	0	0

IPD: Invasive Pneumococcal Disease; STC: Serotype Class; NA: Not Applicable;

PCV13: 13-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PCV20: 20-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine; STCs = serotype classes;

*: left end point of 95%CI.

Populations in each adult age group include those at low risk for pneumococcal disease (healthy

individuals) as well as those with increased risk due to immunocompromising conditions. The

VEd of PCV13 for IPD in healthy adults was based on Bonten *et al*. [20] and in high-risk adults

on Cho *et al.* [21], and VEd of PPSV23 was based on [22]. These individual efficacies were

incorporated into the age-based population-level VEds based on risk distribution by age (Table

S9).

Equivalency was assumed for the new vaccines, which means that new PCVs with additional

STs (e.g PCV15 and PCV20) have equivalent VEds as previous PCVs (PCV13) for shared

serotypes. Overall VEd of PCV13 [18] was used as VEd of PCV15 against STC6-type IPD in

pediatric age groups. PCV13 VEd in adult age groups was not ST-specific and was extended to

additional PCV15 and PCV20 STCs (Table 3).

In a scenario analysis STC-specific VEd for PCV15 was based on immune response of PCV15

relative to PCV13. Results of this scenario analysis are presented in the Supplementary

Appendix.

It was assumed that mean duration of protection from any PCV was 10 years, while PPSV23 was

assumed to have a mean duration of protection of 7.5 years [23].

Carriage clearance rates

218   Annual carriage clearance rates for a given serotype were calculated as the inverse of carriage

219   duration. A literature review was performed to collect data on age and serotype-specific carriage

220   durations. For each age-STC combination the total carriage duration across studies was divided

221   by the total population across studies and normalized by age group. More details on these

222   derivations are available in Section 3.2.4.1.1 of the Supplementary Appendix.

Model calibration

223
To infer the values of the age- and STC-specific probability of acquisition, age- and STC-

specific case-carrier ratios, STC-specific competition parameters, and the STC-specific VEc for

the VTs, the model was calibrated to historical US IPD incidence data from 2000–2019. The

model's fit to historical data of IPD incidence was conducted to minimize the sum of squared

errors. Figure S11 of the Supplementary Appendix provides a visual comparison of the model's

fit to the data, with the fit error shown in each plot. The calibration results, i.e., the values of

fitted parameters, such as invasiveness and carriage transmission probability are higher in

extreme age groups, consistent with conventional wisdom and existing modeling literature.

Pneumococcal dynamics were severely affected by the COVID-19 pandemic [24] through

reduced transmission due to non-pharmaceutical interventions and disruption of routine

healthcare services including vaccination. Since the model does not account for such effects, data

after 2019 were not included in model calibration. Calibration methodology and detailed results

are described further in the Supplementary Appendix.

Calibration target

237
Age-stratified STC-specific IPD incidence per 100,000 in the US from 1998-2019 was used as

calibration target. The annual IPD incidence per 100,000 in the US by age group and STC was

derived from two sources: (i) the available overall (all serotypes) incidence data and (ii) the

serotype distribution data. Overall incidence was obtained from the annual CDC surveillance

reports [25] and the annual serotype distribution data came from Active Bacterial Core

surveillance, CDC [26].

For calibration to NBPP data, pediatric NBPP incidence per 100,000 from 1998–2018 was

obtained from Hu *et al*. [27]. To obtain the counterpart data in adults, all-cause pneumonia

(ACP) incidence was acquired from Truven MarketScan Commercial Claims and Encounters

(January 1, 2012 to December 2020) – a healthcare claims database that contains information

about clinical utilization over time [28]. It was assumed that 11% of ACP had pneumococcal

etiology—NBPP—in US adults [29]. For pediatrics, it was assumed that ST distribution for

NBPP followed that of IPD. For adults, the proportion of NBPP attributable to STCs was

calculated using data from two recent studies [30, 31] and used to construct the STC- and age-

specific calibration data (see Section 5.1 of Supplementary Appendix for additional details).

For AOM calibration, pediatric all-cause AOM incidence per 100,000 from 1998-2018 was

obtained from Hu *et al*. [32] of which 23.8% was pneumococcal attributable [33]. Studies with

ST distribution information for AOM cases [33, 34, 35] were used to construct the STC- and

age-specific data (see Section 5.2 in Supplementary Appendix for additional details).

Using the carriage prevalence profile that corresponded to calibrated IPD incidence, case-carrier

ratios for NBPP and AOM were then calibrated using the historical incidence of each

manifestation. Details on NBPP and AOM calibration, procedure, and results are provided in the

Supplementary Appendix.

Model projections

The calibrated model was then used to compare pneumococcal disease burden assuming either

pediatric PCV13 or PCV15 vaccination. In adults, both PCV15 with PPSV23 or PCV20 have

been recommended for use [36]. A hypothetical combination of these vaccines was constructed.

In addition, given the historic practice, we assumed that healthcare providers may continue to

administer PPSV23 alone. Therefore, to design an adult vaccination scenario (which would be

kept same while comparing the two pediatric vaccination scenarios) it was assumed that of the

vaccinated US adults 80% receive PCV20, 10% receive PCV15+PPSV23, and 10% receive

PPSV23 alone. Since adult vaccination was identical between these two scenarios, the

differences in model outcomes were solely caused by pediatric vaccination. A different adult

vaccination scenario of 50% vaccinated adults receiving PCV20, 25% receiving

PCV15+PPSV23 and 25% receiving PPSV23 (50-25-25 scenario) was examined in an additional

scenario analysis.

The two scenarios are summarized below:

1. Scenario PCV13: Infants receive PCV13 according to assumed VCR. Given assumed

276   VCR among adults 18+, 80% receive PCV20, 10% receive PPSV23, and 10% receive

277   PCV15+PPSV23.

278   2. Scenario PCV15: Infants receive PCV15 according to assumed VCR. Given assumed

279   VCR among adults 18+, 80% receive PCV20, 10% receive PPSV23, and 10% receive

280   PCV15+PPSV23.

Results

IPD data calibration results

As shown in Fig 2 and 3, the model was able to capture historical trends in each of the STCs for

each age group in the US (detailed model fit by STC/age group is given by Figure S11 in the

Supplementary Appendix). Before the introduction of a PCV in the US, PCV7 serotypes (STC1)

dominated the IPD landscape. However, after the introduction of PCV7 in 2000 and prior to the

introduction of PCV13 in 2010, replacement occurred, with the additional PCV13 (excluding

ST3) serotypes increasing in incidence. This replacement behavior was captured by the model by

careful adjustment of the competition parameters. In 2010 PCV13 was introduced and all PCV13

STCs, other than ST3, declined. ST3, both in the model and data, remained relatively constant

across the calibration period. Following PCV13 introduction, all non-vaccine STCs trended

upward.

Prior to PCV7, STC1 outcompeted other STs, but following PCV7 introduction, and the

reduction in STC1 STs, STCs 4,7, and10 were able to expand due to the reduced competitive

pressure from STC1 STs

Fig 2. Calibrated versus observed IPD incidence per 100,000 over time in children age groups. Dashed lines: data;

Solid lines: model outcome.

Fig 3. Calibrated versus observed IPD incidence per 100,000 over time in adult age groups. Dashed lines: data;

Solid lines: model outcome.

IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent

pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent

pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes; V116 = an investigational 21-

valent pneumococcal conjugate vaccine.

Several years of real-world data following the introduction of new vaccines will be necessary to

estimate how new vaccine type STs, such as 22F and 33F (STC6) compete and interact with

other STCs.

The model estimated age- and serotype-specific VEc, which revealed PCV7 to have a greater

impact against the seven serotypes it targeted than PCV13 had on the additional six serotypes it

targeted (TableS18). The model also calculated age- and serotype-specific case-to-carrier ratios

for IPD in the US (Table S17). Results indicated that these case-carrier ratios were highest in the

infants and older adults.

Following the calibration of the model to IPD incidence, which generated age- and STC-specific

carriage acquisition rates, the model was then calibrated to estimate the age- and STC-specific

case-carrier ratios for each of AOM and NBPP. The model captured changes in the serotype

distribution associated with AOM after different vaccine introductions, such as the decline of

five of the additional serotypes included in PCV13 (excluding STC3) (Figure S14). Similarly,

the model replicated reductions in PCV7 STs in 2000 and STC4 (7F, 19A) in 2010 in pediatric

NBPP following the introduction of PCV7 and PCV13 (Figure S13).

Epidemiological projections

The calibrated model was used to make projections in the US for the two scenarios described

above (Fig 4). Projections revealed that PCV15 prevented more cases of IPD, AOM, and NBPP

than PCV13 across all age groups. The reduced incidence of IPD in pediatric age groups under

the PCV15 scenario reflected the direct and indirect benefit due to the added vaccine type

serotypes 22F and 33F, while the lower incidence in adult age groups was due to indirect

protection (i.e., herd immunity) from the pediatric population. It was estimated that over 10

years, PCV15 would reduce about 6% more cases of IPD in the US when compared to PCV13.

This includes around 13.54 more cases averted in children under 2 and 4.82% more cases averted

in adults over the age of 65. With the 50-25-25 scenario (50% vaccinated adults receiving

PCV20 and 25% receiving PCV15+PPSV23 and 25% receiving PPSV23), PCV15 saved about

6.1% more cases of IPD than PCV13 over 10 years, including 4.9% more cases saved in adults

over 65 years of age. As expected, the number of pediatric IPD cases averted remained

unchanged.

Fig 4. IPD incidence per 100,000 projected by the calibrated model. Top: IPD burden, infants and toddlers;

Bottom: Overall IPD burden by age group. Vaccination in adults 18+: 80% receive PCV20, 10% receive PPSV23, and

10% receive PCV15+PPSV23. Vaccine coverage used in these projections is given by Figure S6. Reduced IPD

incidence in adults is a result of indirect protection of pediatric PCV15 vaccination.

IPD = invasive pneumococcal disease; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent

pneumococcal; STs = serotypes; VE = vaccine effectiveness

The model estimated that after 10 years, compared to PCV13, PCV15 will also reduce the

number of NBPP cases by 5.5% and the number of AOM cases by about 3%.

Projected IPD STC distribution

Figure 5 shows the pre-PCV, 2019, and 10 year-projections of IPD incidence in the US. By

2019, PCV7 and PCV13 reduced overall IPD, however ST-distributions shifted with NVTs

replacing VTs over this same period. The third column shows the projected shift in this

distribution following 10 years of PCV15 utilization. STs 22F and 33F (PCV15 non-PCV13) are

diminished with PCV15. There is a clear shift from vaccine-types towards NVTs (Other STs)

through ST replacement. Since PCV20 was implemented in adult age groups (18 and above) in

projection period, IPD in the PCV20 non-PCV15 STC was reduced in adults.

Fig 5. IPD incidence (cases per 100,000) attributed to each STC grouped by vaccine in each model age group.
Model calibrated STC distributions and data at the start and end of calibration period (2000 and 2019 respectively),
and model projected STC distributions after 10 years of PCV15 in infants.

347   IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent

348   pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent

349   pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes

Discussion

An age-structured dynamic model of pneumococcal carriage transmission was developed to

evaluate the epidemiological impact of age-based vaccine policies on pneumococcal diseases. In

this study, we calibrated the model to historical data from the United States, though the model

could be adapted to other countries if data are available. Serotypes were aggregated into serotype

classes (STCs) which allowed disease incidence to be examined by each age and STC

combination.

The model was calibrated to the historical age-specific US IPD incidence data from 2000 to 2019

and used to project future outcomes under different vaccine strategies. The results of this

calibration revealed age- and serotype-specific carriage acquisition probabilities, competition

parameters between STCs, age- and serotype-specific vaccine efficacies against carriage, and

age- and serotype specific case-to-carrier ratios for invasive and non-invasive pneumococcal

disease (IPD, NBPP, and AOM). Calibrated values fell within the range of published estimates

where available or were aligned with calibration estimates of published models.

Probability of carriage acquisition per contact with a colonized individual, which is an age- and

STC-specific parameter, was highest in infants and older adults due to weak immune systems

(i.e., immature in infants [37] and deficient due to age in older adults [38]). This implies that

infants and toddlers (aged 0-4) and older adults are most likely to acquire carriage upon contact

with a colonized individual of any age. These results are consistent with other literature (for

example, see [11, 16, 39]). Case-to-carrier ratios for IPD followed a similar pattern, with infants

and older adults most likely to develop disease from carriage acquisition [40]. Calibration

estimates of case-to-carrier ratios for IPD also fall within the range of published estimates [40,

41, 42, 43].

The calibrated competition parameter estimates correctly reflected the ST replacement in the US

whereby NVTs increased to fill the depleted niche due to target STs declining following PCV7

and PCV13 implementation. Modeling literature highlights the role of ST competition [44] and

some pneumococcal transmission models have included this feature at a higher level or in some

aggregation [12, 45, 46]. However, calibrated ST competition between PCV7 STs against non-

PCV7 STs, and PCV13 STs against non-PCV13 STs, to our knowledge, has not been examined

at such fine granularity before.

Our parameter estimates of STC-specific VEc aligned with those reported in published literature

[47, 48]. Like pneumococcal disease, PCVs are also less protective against ST3 acquisition [49].

This is evident from the relatively low calibrated VEc against ST3 which was also the case with

other published model calibrations that reported ST-specific VEc [11]. Additionally, VEc in

adult age groups is lower than the respective STC-specific VEc in children age groups. Since

carriage acquisition is a prerequisite for pneumococcal disease, protection against acquisition is

the first level of defense that PCVs offer; reduction in acquisition will lead to reduction in

disease.

Since dynamic transmission models estimate the time-dependent dynamics of population-level

susceptibility along with factors that affect the transmission rate (e.g., vaccination status and

carriage acquisition in response to mixing patterns), they are well suited to provide insights into

the indirect protection provided from interventions, such as including vaccination. For example,

a recent study [10] used dynamic transmission models to compare the epidemiologic impact of

switching from PCV13 to PCV15 or PCV20 in infant schedule in England. One of the research

findings of this study reveals that transitioning from PCV13 to PCV15 in the pediatric

vaccination program in England resulted in the unintended consequence of increased incidence

of IPD. However, the implementation of our model to the US data using a different structure and

assumptions demonstrated a decline in IPD cases if a transition from PCV13 to PCV15 were to

occur. Indirect protection of pediatric vaccination on adults which has been observed in

programs where pneumococcal vaccines have been implemented in pediatric programs [50], can

be analyzed in detail using this model. Here, identical vaccination strategies in adults were kept

and the two different vaccination programs in infants, PCV13 versus PCV15, were compared.

Due to indirect protection (i.e., herd immunity), the implementation of PCV15 in pediatrics led

to additional reductions in adult disease attributed to 22F and 33F.

The model does have some limitations. First, because of lack of data to estimate some parameters

such as STC-specific probability of SP acquisition we inferred the values of some of these

parameters by calibrating the model outcomes to historical data. Second, certain serotypes, such

as serotype 3, have evolved under pressure from vaccination [51, 52] but the model does not

account for such evolution, assuming the same properties of STCs throughout the calibration and

projection horizons. Third, since there is very little evidence of meaningful transmission from

adults to children, our model assumes no transmission from adults to children [14] so there is no

indirect effect of vaccinating adults on children. Though this conservative assumption helps

prevent any overstatement of the potential value for adult vaccines, it may limit any implications

on model projections arising from possible adults-to-children transmission. Fourth, including

several STs into a single STC entails strong assumption that STs in the same STC have identical

properties. Fifth, it is assumed that infants either receive full vaccination series or no vaccination

at all. This is a mathematically simplifying assumption to limit parameterization and model

complexity. Sixth, due to lack of data for the efficacy of PCV15 and PCV20, these values were

assumed based on the efficacy of PCV13. Seventh, the model assumes that no immunity is

gained after infection.

The flexibility and accuracy of the model demonstrates promise for future adaptions in other

country settings, where local pneumococcal epidemiology may vary, such as different age-

reporting, vaccine history, vaccine dosing, vaccine efficacies, different STs of interest, or

different policy questions. The model implemented here focused on epidemiological outcomes,

but in future work the model could additionally be used to evaluate the cost-effectiveness of

different vaccines or vaccination strategies. Understanding that certain viral pathogens, such as

respiratory syncytial virus, influenza, and human metapneumovirus may facilitate IPD [53, 54,

55, 56], historical data from these pathogens can also be included into the model to capture some

of the unexplained inter-annual variation in IPD incidence.

Acknowledgements: The authors acknowledge the support of Eric Sarpong in the acquisition of

NBPP incidence data in adults, John Lang for his constructive feedback on the manuscript and

supplementary appendix, and the Scientific Advisory Committee composed of multiple experts

for their advice throughout model development and application.

Conflicts of Interest: TM, KB, RO, OS, and EE are full-time employees of Merck Sharp &

Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may hold stock or stock

options in Merck & Co., Inc., Rahway, NJ, USA. GM and RN are consultants whose institution

(Wolfram Research, Inc., Champaign IL, USA) is paid by Merck Sharp & Dohme. RN may hold

stock or stock options in Merck & Co., Inc., Rahway, NJ, USA.

References

[1] "Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae," Centers for Disease Control and Prevention, 1998-2021. [Online]. Available: https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf. [Accessed 17 April 2024].

[2] B. Wahl, K. L. O'Brien, A. Greenbaum, A. Majumder, L. Liu, Y. Chu, I. Lukšić, H. Nair and D. McAllister, "Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15," *Lancet Glob Health,* vol. 6, pp. e744-e757, 2018.

[3] R. Gierke, A. P. Wodi and M. Kobayashi, "Pink Book Chapter 17: Pneumococcal Disease," Centers for Disease Control and Prevention, [Online]. Available: https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html. [Accessed 13 January 2025].

[4] W. Hausdorff, D. Feikin and K. Klugman, "Epidemiological differences among pneumococcal serotypes," *Lancet Infect Dis,* vol. 5, pp. 83-93, 2005.

[5] I. Jagne, C. von Mollendorf, A. Wee-Hee, B. Ortika, C. Satzke and F. Russell, "A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age," *Vaccine,* vol. 41, pp. 3028-37, 2023.

[6] B. Simell, K. Auranen, H. Kayhty, D. Goldblatt, R. Dagan, K. O'Brien and PneumoCarr, "The fundamental link between pneumococcal carriage and disease," *Expert Rev Vaccines,* vol. 11, pp. 841-55, 2012.

[7] D. M. Weinberger, R. Malley and M. Lipsitch, "Serotype replacement in disease after pneumococcal vaccination," *Lancet,* vol. 6736, no. 10, pp. 1962-73, 2011.

[8] N. Ouldali, E. Varon, C. Levy, F. Angoulvant, S. Georges, M.-C. Ploy, M. Kempf and J. Cremniter, "Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study," *Lancet Infect Dis,* vol. 21, pp. 137-47, 2021.

[9] K. Prem, A. Cook and M. Jit, "Projecting social contact matrices in 152 countries using contact surveys and demographic data," *PLoS Comput Biol,* vol. 13, 2017.

[10] Y. H. Choi, M. Bertran, D. J. Litt, S. N. Ladhani and E. Miller, "Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study," *Lancet Public Health,* vol. 9, pp. e654-e663, 2024.

[11] M. Wasserman, A. Lucas, D. Jones, M. Wilson, B. Hilton, A. Vyse, H. Madhava, A. Brogan, M. Slack and R. Farkouh, "Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK," *Epidemiol Infect,* vol. 146, no. 14, pp. 1797-806, 2018.

[12] A. Melegaro, Y. Choi, R. George, W. Edmunds, E. Miller and N. Gay, "Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease," *BMC Infect Dis,* vol. 90, p. 10, 2010.

[13] C. Bottomley, A. Roca, P. Hill, B. Greenwood and V. Isham, "A mathematical model of serotype replacement in pneumococcal carriage following vaccination.," *J R Soc Interface,* vol. 10, no. 89, p. 20130786., 2013.

[14] B. Althouse, L. Hammitt, L. Grant, B. Wagner, R. Reid, F. Larzelere-Hinton, R. Weatherholtz, K. Klugman, G. Rodgers and K. O'Brien, "Identifying transmission routes of Streptococcus pneumoniae and sources of acquisitions in high transmission communities," *Epidemiol Infect,* vol. 145, no. 13, pp. 2750-8, 2017.

[15] L.-M. Steurer, M. Hetzmannseder, B. Willinger, P. Starzengruber, C. Mikula-Pratschke, A. Kormann-Klement, M. Weber, A. Berger and A. Grill, "Streptococcus pneumoniae colonization in health care professionals at a tertiary university pediatric hospital," *Clin Microbiol Infect Dis,* vol. 41, pp. 971-976, 2022.

[16] J. F. Mosser, L. R. Grant, E. V. Millar, R. C. Weatherholtz, D. M. Jackson, B. Beall, M. J. Craig, R. Reid, M. Santosham and K. L. O'Brien, "Nasopharyngeal carriage and transmission of Streptococcus pneumoniae in American Indian households after a decade of pneumococcal conjugate vaccine use," *PLoS One,* vol. 9, 2014.

[17] C. G. Whitney, T. Pilishvili, M. M. Farley, W. Schaffner, A. S. Craig, R. Lynfield, A.-C. Nyquist, K. A. Gershman, M. Vazquez, N. M. Bennett, A. Reingold, A. Thomas, M. P. Glode and E. R. Zell, "Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study," *Lancet,* vol. 368, no. 9546, pp. 1495-502, 2006.

[18] M. R. Moore, R. Link-Gelles, W. Schaffner, R. Lynfield, C. Holtzman, L. H. Harrison, S. M. Zansky, J. B. Rosen, A. Reingold, K. Scherzinger, A. Thomas, R. E. Guevara and T. Motala, "Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study," *Lancet Respir Med,* vol. 4, no. 5, pp. 399-406, 2016.

[19] P. Tamara Pilishvili, "13-valent pneumococcal conugate vaccine (PCV13) effects on disease caused by serotype 3 (Advisory Committee on Immunization Practices)," 28 February 2019. [Online]. Available: https://stacks.cdc.gov/view/cdc/78091.

[20] M. J. M. Bonten, S. M. Huijts, M. Bolkenbaas, C. Webber, S. Patterson, S. Gault, C. H. v. Werkhoven, A. M. M. v. Deursen, E. A. M. Sanders, T. J. M. Verheij, M. Patton, A. McDonough, A. Moradoghli-Haftvani, H. Smith and T. Mellelieu, "Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults," *N Engl J Med,* vol. 372, no. 12, pp. 1114-25, 2015.

[21] B.H.Cho, C. Stoecker, R. Lin-Gelles and M.R.Moore, "Cost-effectiveness of administering 13-valent pneumococcalconjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions," *Vaccine,* vol. 31, pp. 6011-6021, 2013.

[22] A. J. Leidner, "Summary of three economic models assessing pneumococcal vaccines in US adults (ACIP Presentation Slides: September 29, 2021 Meeting)," 29 09 2021. [Online]. Available: www.cdc.gov/vaccines/acip/meetings/slides-2021-09-29.html. [Accessed 04 11 2024].

[23] M. Treskova, S. M. Scholz and A. Kuhlmann, "Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions," *PharmacoEconomics,* vol. 37, pp. 1093-1127, 2019.

[24] R. Dagan, D. Danino and D. Weinberger, "The Pneumococcus-Respiratory Virus Connection-Unexpected Lessons From the COVID-19 Pandemic," *JAMA Netw Open,* vol. 5, 2022.

[25] "Active Bacterial Core surveillance; Surveillance Reports," Centers for Disease Control and Prevention, 13 09 2024. [Online]. Available: https://www.cdc.gov/abcs/reports/index.html. [Accessed 10 10 2024].

[26] "1998-2022 Serotype Data for Invasive Pneumococcal Disease Cases by Age Group from Active Bacterial Core surveillance," Active Bacterial Core Surveillance, 22 07 2024. [Online]. Available: https://data.cdc.gov/Public-Health-Surveillance/1998-2022-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p/about_data. [Accessed 19 09 2024].

[27] T. Hu, E. M. Sarpong, Y. Song, N. Done, Q. Liu, E. Lemus-Wirtz, J. Signorovitch, S. Mohanty and T. Weiss, "Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis," *Pneumonia (Nathan),* vol. 15, no. 1, 2023.

[28] A. M. Butler, K. B. Nickel, R. A. Overman and M. A. Brookhart, "IBM MarketScan Research Databases," in *Sturkenboom, M., Schink, T. (eds) Databases for Pharmacoepidemiological Research. Springer Series on Epidemiology and Public Health ((SSEH)),* Springer, 2021, pp. 243-251.

[29] M. J. Choi, J. Y. Song, H. J. Cheong, J. H. Jeon, S. H. Kang, E. J. Jung, J. Y. Noh and W. J. Kim, "Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes," *J Infect Chemother,* vol. 21, no. 9, pp. 672-9, 2015.

[30] R. Isturiz, L. Grant and S. Gray, "Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults," *Clin Infect Dis,* vol. 73, no. 7, pp. 1216-22, 2021.

[31] R. E. Isturiz, J. Ramirez, W. H. Self, C. G. Grijalva, F. L. Counselman, G. Volturo, L. Ostrosky-Zeichner, P. Peyrani, R. G. Wunderink, R. Sherwin, J. S. Overcash, S. P. Oliva and T. File, "Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia," *Vaccine,* vol. 37, no. 25, pp. 3352-61, 2019.

[32] T. Hu, N. Done, T. Petigara, S. Mohanty, Y. Song, Q. Liu, E. Lemus-Wirtz, J. Signorovitch, E. Sarpong and T. Weiss, "Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018," *BMC Infec Dis,* vol. 22, no. 1, 2022.

[33] R. Kaur, N. Fuji and M. E. Pichichero, "Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019," *Eur J Clin Microbiol Infect Dis,* vol. 41, no. 1, pp. 37-44, 2022.

[34] S. L. Block, J. Hedrick, C. J. Harrison, R. Tyler, A. Smith, R. Findlay and E. Keegan, "Pneumococcal serotypes from acute otitis media in rural Kentucky," *Pediatr Infect Dis J,* vol. 21, no. 9, pp. 859-65, 2002.

[35] J. R. Casey, D. G. Adlowitz and M. E. Pichichero, "New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine," *Pediatr Infect Dis J,* vol. 29, no. 4, pp. 304-9, 2010.

[36] M. Kobayashi, J. L. Farrar, R. Gierke, A. J. Leidner, D. Campos-Outcalt, R. L. Morgan, S. S. Long, K. A. Poehling and A. L. Cohen, "Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022," *MMWR,* vol. 71, pp. 1174-81, 2022.

[37] L. Lambert and F. Culley, "Innate Immunity to Respiratory Infection in Early Life," *Front Immunol,* vol. 8, 2017.

[38] C. Krone, K. van-de-Groep, K. Trzcinski, E. Sanders and D. Bogaert, "Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions," *Lancet Respir Med,* vol. 2, pp. 141-53, 2014.

[39] A. Melegaro, N. Gay and G. Medley, "Estimating the transmission parameters of pneumococcal carriage in households," *Epidemiol Infect,* vol. 132, pp. 433-41, 2004.

[40] Y. Choi, M. Jit, S. Flasche, N. Gay and E. Miller, "Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales," *PLoS One.,* vol. 7, no. 7, p. e39927, 2012.

[41] J. Southern, N. Andrews, P. Sandu, C. L. Sheppard, P. A. Waight, N. K. Fry, A. J. V. Hoek and E. Miller, "Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England," *PLoS One,* vol. 13, 2018.

[42] I. Yildirim, B. Little, J. Finkelstein, G. Lee, W. Hanage, K. Shea and S. Pelton, "Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts' children to relatively low invasiveness," *Vaccine,* vol. 35, pp. 4002-9, 2017.

[43] A. Lochen and R. Anderson, "Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations," *Clin Microbiol Infect,* vol. 26, no. 1, pp. 60-70, 2020.

[44] M. Lipsitch, "Vaccination against colonizing bacteria with multiple serotypes," *Proc Natl Acad Sci U.S.A.,* vol. 94, no. 12, pp. 6571-6, 1997.

[45] G. Masala, M. Lipsitch, C. Bottomley and S. Flasche, "Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination," *J R Soc Interface,* vol. 14, no. 136, 2017.

[46] E. De-Cao, A. Melegaro, R. Klok and M. Postma, "Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling," *PLoS One,* vol. 9, no. 4, p. e89415., 2014.

[47] E. Gjini, "Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7," *Sci Rep,* vol. 7, no. 1, p. 3049, 2017.

[48] H. Rinta-Kokko, R. Dagan, N. Givon-Lavi and K. Auranen, "Estimation of vaccine efficacy against acquisition of pneumococcal carriage," *Vaccine,* vol. 27, no. 29, pp. 3831-7, 2009.

[49] R. Lapidot, K. Shea, I. Yildirim, H. Cabral, S. Pelton and ". M. D. O. P. Health", "Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts," *Pathogens,* vol. 9, 2020.

[50] E. Miller, N. Andrews, P. Waight, M. Slack and R. George, "Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study," *Lancet Infect Dis,* vol. 11, pp. 760-8, 2011.

[51] N. Groves, C. L. Sheppard, D. Litt, S. Rose, A. S. N. Njoku, S. Rodrigues, Z. Amin-Chowdhury, N. Andrews, S. Ladhani and N. K. Fry, "Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader," *Genes (Basel),* vol. 10, 2019.

[52] T. Azarian, P. K. Mitchell, M. Georgieva, C. M. Thompson, A. Ghouila, A. J. Pollard, A. v. Gottberg, M. d. Plessis, M. Antonio, B. A. Kwambana-Adams, S. C. Clarke, D. Everett, J. Cornick, E. Sadowy, W. Hryniewicz, A. Skoczynska, J. C. Moisi, L. McGee, B. Beall, B. J. Metcalf, R. F. Brieman, P. L. Ho, R. Reid, K. L. O'Brien, R. A. Gladstone, s. D. Bentley and W. P. Hanage, "Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci," *PLoS Pathog,* vol. 14, 2018.

[53] S. Ben-Shimol, D. Greenberg, G. Hazan, Y. Shemer-Avni, N. Givon-Lavi and R. Dagan, "Seasonality of both bacteremic and nonbacteremic pneumonia coincides with viral lower respiratory tract infections in early childhood, in contrast to nonpneumonia invasive pneumococcal disease, in the pre-pneumococcal conjugate vaccine era," *Clin Infect Dis,* vol. 60, no. 9, pp. 1984-7, 2015.

[54] D. M. Weinberger, L. R. Grant, C. A. Steiner, R. Weatherholtz, M. Santosham, C. Viboud and K. L. O'Brien, "Seasonal Drivers of Pneumococcal Disease Incidence: Impact of Bacterial Carriage and Viral Activity," *CID,* vol. 584, 2014.

[55] D. M. Weinberger, Z. B. Harboe, C. Viboud, T. G. Krause, M. Miller, K. Mølbak and H. B. Konradsen, "Serotype-specific effect of influenza on adult invasive pneumococcal pneumonia," *J Infect Dis,* vol. 208, no. 8, pp. 1274-80, 2013.

[56] L. G. Stensballe, T. Hjuler, A. Andersen, M. Kaltoft, H. Ravn, P. Aaby and E. A. F. Simoes, "Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study," *Clin Infect Dis,* vol. 46, no. 8, pp. 1165-71, 2008.

Supporting information

444   **S1 Text. Supplementary Appendix**

IPD incidence (per 100,000)

■ Data ■ Strategy PCV13 ■ Strategy PCV15